Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02720094 · ClinicalTrials.gov registry record · Phase 2
Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 4,570
- Enrollment target
NCT02720094 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 4,570 participants.
The verdict
NCT02720094, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4,570 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
Interventions
- DRUG CAB LA
- DRUG Cabotegravir Oral Tablet
- DRUG TDF/FTC tablets
- DRUG Placebo for TDF/FTC tablets
- DRUG Placebo for cabotegravir oral tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,570 participants |
| Start Date | 2016-12-19 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02720094
The ClinicalTrials.gov registry entry for NCT02720094 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4,570 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which CAB LA is the first listed.
NCT02720094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02720094 about?
NCT02720094 is a clinical study titled "Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men". This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
What is the current status of trial NCT02720094?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4,570 participants. The study started on 2016-12-19. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT02720094?
The interventions under investigation include: CAB LA (DRUG), Cabotegravir Oral Tablet (DRUG), TDF/FTC tablets (DRUG), Placebo for TDF/FTC tablets (DRUG), Placebo for cabotegravir oral tablet (DRUG).
Who is sponsoring clinical trial NCT02720094?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.